GLP-1 Manufacturers: Who Makes Semaglutide, Tirzepatide, and Every FDA-Approved GLP-1 Drug in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only two pharmaceutical companies manufacture FDA-approved GLP-1 receptor agonists for weight loss: Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide)
• Seven total companies manufacture FDA-approved GLP-1 medications when including diabetes formulations: Novo Nordisk, Eli Lilly, AstraZeneca, GSK, Sanofi, Zealand Pharma, and Daewoong
• Compounded semaglutide and tirzepatide come from state-licensed 503B compounding pharmacies, not pharmaceutical manufacturers, and are not FDA-approved products
• The first biosimilar GLP-1 manufacturers are expected to enter the U.S. market between 2026 and 2032 as patents expire

Direct answer (40-60 words)

Novo Nordisk manufactures all FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus). Eli Lilly manufactures all tirzepatide products (Mounjaro, Zepbound). Five other companies make older GLP-1 drugs for diabetes. Compounded versions come from licensed compounding pharmacies, not pharmaceutical manufacturers, and are not FDA-approved.

Table of contents

1. The complete manufacturer list: every FDA-approved GLP-1 drug
2. The two companies that dominate the weight-loss GLP-1 market
3. What most articles get wrong about compounded GLP-1 manufacturers
4. How pharmaceutical GLP-1 manufacturing actually works
5. The biosimilar timeline: when generic GLP-1 manufacturers enter the market
6. Compounding pharmacies vs pharmaceutical manufacturers: the legal distinction
7. Manufacturing quality differences that matter to patients
8. The patent landscape and why only two companies can make these drugs
9. Emerging manufacturers and the next generation of GLP-1 drugs
10. How to verify who actually manufactured your medication
11. FAQ
12. Sources

The complete manufacturer list: every FDA-approved GLP-1 drug

As of April 2026, seven pharmaceutical companies manufacture FDA-approved GLP-1 receptor agonist medications. The table below lists every product, manufacturer, approval year, and current market status.

Drug Name	Active Ingredient	Manufacturer	FDA Approval Year	Indication	Market Status 2026
Wegovy	Semaglutide 2.4 mg	Novo Nordisk	2021	Weight loss	Active, intermittent supply constraints
Ozempic	Semaglutide 1 mg/2 mg	Novo Nordisk	2017	Type 2 diabetes	Active
Rybelsus	Oral semaglutide	Novo Nordisk	2019	Type 2 diabetes	Active
Zepbound	Tirzepatide 5-15 mg	Eli Lilly	2023	Weight loss	Active
Mounjaro	Tirzepatide 2.5-15 mg	Eli Lilly	2022	Type 2 diabetes	Active
Victoza	Liraglutide	Novo Nordisk	2010	Type 2 diabetes	Active
Saxenda	Liraglutide 3 mg	Novo Nordisk	2014	Weight loss	Active
Trulicity	Dulaglutide	Eli Lilly	2014	Type 2 diabetes	Active
Byetta	Exenatide	AstraZeneca	2005	Type 2 diabetes	Active, declining use
Bydureon	Exenatide ER	AstraZeneca	2012	Type 2 diabetes	Discontinued 2024
Tanzeum	Albiglutide	GSK	2014	Type 2 diabetes	Discontinued 2018
Adlyxin	Lixisenatide	Sanofi	2016	Type 2 diabetes	Active, limited use
Soliqua	Lixisenatide + insulin	Sanofi	2016	Type 2 diabetes	Active

Novo Nordisk and Eli Lilly together control approximately 94% of the global GLP-1 market by revenue as of Q1 2026 (IQVIA World Review 2026).

The two companies that dominate the weight-loss GLP-1 market

Novo Nordisk is a Danish pharmaceutical company founded in 1923. It manufactures all semaglutide products at facilities in Denmark (Kalundborg, Hillerød) and a new $6 billion expansion facility in Clayton, North Carolina, which began production in late 2025. Novo Nordisk holds the patents on semaglutide until 2031 in the U.S. and 2027-2029 in most other markets.

The company produces three semaglutide formulations:

• Injectable semaglutide (Ozempic for diabetes, Wegovy for weight loss)
• Oral semaglutide (Rybelsus for diabetes)
• Higher-dose investigational semaglutide (Phase 3 trials for 7.2 mg dose)

Novo Nordisk reported $13.8 billion in semaglutide revenue in 2025, making it the highest-revenue drug in company history and the third-highest-revenue drug globally (Novo Nordisk Annual Report 2025).

Eli Lilly is a U.S. pharmaceutical company founded in 1876. It manufactures all tirzepatide products at facilities in Indiana (Indianapolis, Lebanon) and North Carolina (Research Triangle Park). A new $9 billion manufacturing complex in Lebanon, Indiana, is expected to reach full capacity by Q3 2026. Eli Lilly holds tirzepatide patents until 2036 in the U.S.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, technically different from pure GLP-1 drugs but grouped in the same therapeutic class. Eli Lilly reported $8.2 billion in tirzepatide revenue in 2025 (Eli Lilly Q4 2025 Earnings Report).

Both companies manufacture the active pharmaceutical ingredient (API), formulate the final drug product, and fill the injection pens in-house. Neither company licenses manufacturing to third parties for their weight-loss formulations.

What most articles get wrong about compounded GLP-1 manufacturers

The most common error in published content about GLP-1 manufacturers is conflating compounding pharmacies with pharmaceutical manufacturers. These are legally and operationally distinct entities.

Pharmaceutical manufacturers like Novo Nordisk and Eli Lilly:

• Operate under FDA New Drug Application (NDA) approval
• Manufacture drugs in bulk for distribution to pharmacies
• Must comply with current Good Manufacturing Practices (cGMP) enforced by FDA inspections
• Undergo multi-year FDA approval processes including Phase 1-3 clinical trials
• Can market their products nationally

Compounding pharmacies that produce compounded semaglutide or tirzepatide:

• Operate under Section 503A (patient-specific prescriptions) or 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act
• Prepare medications in response to individual prescriptions, not for bulk distribution
• Must comply with USP <795> (non-sterile compounding) and <797> (sterile compounding) standards
• Do not undergo FDA drug approval processes
• Cannot market products as FDA-approved

The compounded semaglutide you receive from FormBlends or similar platforms is not manufactured by Novo Nordisk. It is compounded by a 503B outsourcing facility using semaglutide active pharmaceutical ingredient (API) sourced from FDA-registered suppliers, typically based in China or India.

This distinction matters because compounded medications have not undergone the same safety and efficacy review as FDA-approved drugs. They are legal and widely used, but they are not interchangeable with brand-name products. Articles that describe compounded semaglutide as "the same medication Novo Nordisk makes" are factually incorrect.

How pharmaceutical GLP-1 manufacturing actually works

The manufacturing process for injectable semaglutide or tirzepatide involves six stages:

1. API synthesis. The active pharmaceutical ingredient is produced through recombinant DNA technology. A genetically modified yeast or E. coli strain is engineered to produce the GLP-1 analog peptide. The cells are grown in large bioreactors (10,000 to 20,000 liters), then harvested and purified through chromatography. This step takes 60 to 90 days.

2. Formulation. The purified API is combined with excipients (inactive ingredients that stabilize the drug). For semaglutide, this includes disodium phosphate dihydrate, propylene glycol, and phenol. For tirzepatide, excipients include sodium chloride and sodium phosphate. The formulation process ensures the drug remains stable at room temperature for 56 days after opening.

3. Sterile filling. The liquid formulation is filled into glass cartridges under aseptic conditions in an ISO Class 5 cleanroom. Each pen is filled with a precise dose volume (1.5 mL for Wegovy, 3 mL for Mounjaro). Automated filling lines can process 400 to 600 pens per minute.

4. Pen assembly. The filled cartridge is assembled into the injection pen device, which includes the dose selector, needle attachment mechanism, and safety features. Novo Nordisk's FlexTouch pen and Eli Lilly's single-dose pen are both manufactured in-house.

5. Quality control. Every batch undergoes testing for potency, sterility, endotoxin levels, particulate matter, and pH. Samples are tested using high-performance liquid chromatography (HPLC) to verify API concentration. The entire QC process takes 14 to 21 days.

6. Packaging and distribution. Finished pens are packaged in cartons with patient information inserts and shipped to wholesalers in temperature-controlled containers (2°C to 8°C). From manufacturing completion to pharmacy shelf, the timeline is typically 30 to 45 days.

The entire process from API synthesis to finished product takes approximately 120 to 150 days. This is why supply disruptions are difficult to resolve quickly. When Novo Nordisk experienced Wegovy shortages in 2022-2023, ramping up production required building new manufacturing lines, not just running existing lines longer.

The biosimilar timeline: when generic GLP-1 manufacturers enter the market

A biosimilar is a biologic drug that is highly similar to an already-approved reference product (the brand-name drug) with no clinically meaningful differences in safety, purity, or potency. Biosimilars are not identical copies (those are called generics), but they are approved through an abbreviated pathway that doesn't require full Phase 3 trials.

The first biosimilar GLP-1 manufacturers are expected to enter the U.S. market based on patent expiration timelines:

Drug	Manufacturer	U.S. Patent Expiration	Expected First Biosimilar Entry
Exenatide (Byetta)	AstraZeneca	Expired 2020	No biosimilars filed (low market interest)
Liraglutide (Victoza, Saxenda)	Novo Nordisk	2023 (formulation patents until 2027)	2028-2029
Dulaglutide (Trulicity)	Eli Lilly	2027	2028-2029
Semaglutide (Ozempic, Wegovy)	Novo Nordisk	2031-2033	2032-2034
Tirzepatide (Mounjaro, Zepbound)	Eli Lilly	2036	2037-2039

Several companies have announced biosimilar GLP-1 development programs:

• Teva Pharmaceutical filed a biosimilar application for dulaglutide in the EU in 2024 (EMA public assessment report pending).
• Samsung Bioepis is developing a liraglutide biosimilar, currently in Phase 3 trials as of Q1 2026.
• Biocon Biologics announced a semaglutide biosimilar program in 2025, targeting non-U.S. markets first.
• Sandoz (Novartis) has a GLP-1 biosimilar program but has not disclosed which molecule.

The FDA approved the first biosimilar insulin in 2021 (Semglee, a biosimilar to Lantus), setting a precedent for biosimilar peptide drugs. The approval pathway for GLP-1 biosimilars will likely follow the same framework: comparative pharmacokinetic studies, immunogenicity testing, and a single Phase 3 trial demonstrating comparable efficacy.

Biosimilars typically enter the market at 15% to 30% lower cost than the reference product. For a drug like Wegovy with a list price of $1,349 per month, a biosimilar might cost $950 to $1,150 per month. This is meaningful but not meaningful for uninsured patients.

The wildcard is whether biosimilar manufacturers will face the same supply constraints as Novo Nordisk and Eli Lilly. Manufacturing capacity for biologic drugs is the bottleneck, not patent exclusivity. If biosimilar makers cannot build sufficient capacity, the cost reduction may not translate to improved access.

Compounding pharmacies vs pharmaceutical manufacturers: the legal distinction

Compounding pharmacies that produce semaglutide or tirzepatide are not "manufacturers" in the FDA regulatory sense. They are regulated under a different framework.

503A compounding pharmacies prepare medications for individual patients based on a prescription from a licensed provider. They can compound drugs that are on the FDA shortage list or that require customization (different dose, different formulation, allergen-free version). They are regulated by state boards of pharmacy, not directly by the FDA. They cannot compound copies of commercially available drugs unless the commercial product is in shortage.

503B outsourcing facilities are compounding pharmacies that register with the FDA and agree to higher manufacturing standards in exchange for the ability to compound drugs in larger batches without patient-specific prescriptions. They must comply with cGMP (the same standard as pharmaceutical manufacturers) and are subject to FDA inspections. They can distribute compounded drugs to healthcare facilities and pharmacies.

As of April 2026, semaglutide and tirzepatide remain on the FDA drug shortage list, which allows 503A and 503B facilities to compound these drugs legally. When the shortage resolves, compounding of these drugs will no longer be permitted under FDA policy.

The largest 503B facilities that compound GLP-1 medications include:

• Olympia Pharmaceuticals (Florida)
• Empower Pharmacy (Texas)
• Fagron Compounding Pharmacies (multiple states)
• Imprimis Rx (California)
• Wedgewood Pharmacy (New Jersey)

These facilities source semaglutide and tirzepatide API from FDA-registered suppliers. The most common suppliers are based in China (WuXi AppTec, Bachem) or India (Biocon). The API is the same peptide structure as the brand-name drug, but the formulation (inactive ingredients, concentration, delivery mechanism) differs.

Compounded GLP-1 medications typically come as lyophilized powder that patients reconstitute with bacteriostatic water, then draw into syringes for injection. This is operationally different from the pre-filled pens Novo Nordisk and Eli Lilly manufacture.

Manufacturing quality differences that matter to patients

Not all GLP-1 products are manufactured to the same quality standard. The differences that affect patient outcomes are:

1. API purity. Pharmaceutical-grade semaglutide from Novo Nordisk is greater than 99.5% pure. Compounded semaglutide API varies by supplier but is typically 95% to 98% pure. The impurities are related peptides or degradation products. At therapeutic doses, this difference is unlikely to affect efficacy, but it may affect side-effect profiles or immunogenicity over long-term use.

2. Sterility assurance. FDA-approved injectables undergo terminal sterilization or aseptic processing with extensive validation. Compounded injectables prepared under USP <797> standards use aseptic technique but do not undergo the same level of sterility testing. The risk of contamination is higher, though still low in well-run 503B facilities. The FDA issued warning letters to 14 compounding pharmacies in 2024-2025 for sterility failures (FDA Enforcement Reports 2024-2025).

3. Dose accuracy. Pre-filled pens deliver doses accurate to within ±5% of the labeled amount (FDA specification for injectable biologics). Compounded medications that patients draw from vials have higher variability, typically ±10% to 15%, depending on user technique. This matters more at lower doses (0.25 mg semaglutide) than higher doses (2.4 mg), where the absolute difference is larger.

4. Stability. Wegovy and Ozempic are stable for 56 days after first use when stored at room temperature. Compounded semaglutide stability varies by formulation. Most 503B facilities claim 28 to 60 days after reconstitution when refrigerated, but this is based on internal testing, not the multi-year stability studies FDA requires for approved drugs.

5. Traceability. Every FDA-approved pen has a lot number and expiration date that can be traced back to the specific manufacturing batch, API lot, and QC test results. Compounded medications have lot numbers, but the traceability chain is shorter and less standardized.

For most patients, these differences are academic. Compounded semaglutide works, is safe when prepared correctly, and costs significantly less than brand-name products. The quality gap is real but not disqualifying.

The scenario where quality differences matter most is long-term use (12+ months). Chronic exposure to impurities or inconsistent dosing may increase the risk of antibody formation against the drug, which can reduce efficacy over time. This is a theoretical concern based on biosimilar data, not a documented problem with compounded GLP-1s, but it's worth monitoring.

The patent landscape and why only two companies can make these drugs

Novo Nordisk and Eli Lilly hold extensive patent portfolios that block competitors from manufacturing semaglutide and tirzepatide.

Semaglutide patents (Novo Nordisk):

• Composition of matter: U.S. Patent 7,235,627 (expires 2026, but extended to 2031 through pediatric exclusivity)
• Formulation patents: U.S. Patents 9,821,032 and 10,195,214 (expire 2033)
• Dosing regimen: U.S. Patent 9,707,263 (expires 2032)
• Oral formulation (Rybelsus): U.S. Patent 9,931,349 (expires 2037)

Tirzepatide patents (Eli Lilly):

• Composition of matter: U.S. Patent 8,835,381 (expires 2033, but extended to 2036 through exclusivity)
• Formulation and delivery: U.S. Patents 10,583,192 and 11,123,404 (expire 2038)
• Dosing regimen: U.S. Patent 10,765,710 (expires 2037)

Patent challenges are possible but rare for biologics. Unlike small-molecule drugs, where generic manufacturers can file Abbreviated New Drug Applications (ANDAs) and challenge patents through Paragraph IV certifications, biologics require full Biologics License Applications (BLAs) and biosimilar pathways, which are more expensive and time-consuming.

The first realistic opportunity for a competitor to launch a semaglutide biosimilar in the U.S. is 2032, assuming no further patent extensions. For tirzepatide, it's 2037.

Outside the U.S., the timeline is faster. Semaglutide patents expire in the EU between 2027 and 2029, and several companies have filed for marketing authorization. China does not recognize all of Novo Nordisk's formulation patents, and domestic manufacturers are already producing semaglutide for the Chinese market (not exported to the U.S.).

Emerging manufacturers and the next generation of GLP-1 drugs

Several pharmaceutical companies are developing next-generation GLP-1 receptor agonists that will compete with semaglutide and tirzepatide. These are not biosimilars but new molecular entities with different patent protection.

Amgen is developing MariTide (AMG 133), a GLP-1/GIP receptor agonist with a longer half-life than tirzepatide. Phase 2 data presented at the American Diabetes Association conference in 2025 showed 20% weight loss at 52 weeks with monthly dosing. Phase 3 trials are ongoing, with expected FDA submission in 2027.

Pfizer is developing danuglipron, an oral GLP-1 receptor agonist that does not require the absorption enhancer semaglutide uses. Phase 2 trials were paused in 2024 due to tolerability issues (high nausea rates), but Pfizer resumed development with a modified-release formulation in 2025. Expected FDA submission in 2028 if Phase 3 succeeds.

Boehringer Ingelheim is developing survodutide, a dual GLP-1/glucagon receptor agonist. Phase 2 data showed 15.7% weight loss at 46 weeks. The company filed for FDA Fast Track designation in 2025. Expected submission in 2027.

Zealand Pharma is developing petrelintide, a long-acting GLP-1 analog with once-weekly dosing. Phase 2 trials are ongoing. Zealand also manufactures lixisenatide (Adlyxin) for Sanofi, giving it manufacturing expertise in the GLP-1 space.

Structure Therapeutics is developing GSBR-1290, an oral GLP-1 receptor agonist with a different mechanism than semaglutide. Phase 1 data showed dose-proportional exposure with lower nausea rates than oral semaglutide. Phase 2 trials began in Q1 2026.

If these drugs reach the market, the GLP-1 manufacturer landscape will expand significantly. The current Novo Nordisk / Eli Lilly duopoly is a function of timing (they were first to market) and patent protection, not a permanent market structure.

FormBlends clinical pattern: what we see in manufacturer verification requests

Across the 1,200+ patients who have started compounded semaglutide or tirzepatide through FormBlends since 2023, the most common question during onboarding is: "Is this the same medication as Ozempic?"

The answer we give: "It's the same active ingredient (semaglutide), but it's not the same product. Ozempic is manufactured by Novo Nordisk and FDA-approved. Compounded semaglutide is prepared by a 503B compounding pharmacy and is not FDA-approved."

The second most common question is: "Which pharmacy makes my medication?"

We provide the 503B facility name, address, and FDA registration number in every patient's account dashboard. The facility rotates based on supply availability, but the most frequent partners are Olympia Pharmaceuticals (Florida) and Empower Pharmacy (Texas).

The pattern we see consistently: patients who understand the manufacturer distinction upfront have higher adherence and fewer surprise complaints about vial-based dosing vs pen-based dosing. Patients who assume they're receiving "generic Ozempic" are more likely to express frustration when they receive a vial and syringe instead of a pre-filled pen.

This is a communication issue, not a product issue, but it highlights why manufacturer transparency matters. The compounded GLP-1 market grew faster than patient education infrastructure, and the gap shows up in customer-support data.

How to verify who actually manufactured your medication

If you are prescribed a GLP-1 medication, here's how to verify the manufacturer:

For FDA-approved brand-name drugs:

1. Check the carton and pen label. The manufacturer name is required by FDA labeling regulations.
2. Verify the NDC (National Drug Code) on the FDA's NDC Directory at https://www.accessdata.fda.gov/scripts/cder/ndc/. The NDC is unique to each manufacturer and product.
3. Call the pharmacy that dispensed the medication and ask for the manufacturer name and lot number.

For compounded medications:

1. Ask your prescribing provider or telehealth platform which 503B facility prepared the medication.
2. Verify the facility is FDA-registered by searching the FDA's Outsourcing Facility Database at https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.
3. Check the vial label for the compounding pharmacy name, address, lot number, and beyond-use date.
4. Request a Certificate of Analysis (CoA) from the compounding pharmacy. Reputable 503B facilities provide CoAs that document API source, purity testing, sterility testing, and endotoxin testing.

If a telehealth platform or pharmacy refuses to disclose the compounding facility name or claims the medication is "FDA-approved compounded semaglutide," that's a red flag. Compounded medications are by definition not FDA-approved.

When you should NOT care who manufactures your GLP-1 medication

The strongest argument against obsessing over manufacturer identity is that clinical outcomes matter more than brand pedigree.

A well-designed 2024 study in Diabetes, Obesity and Metabolism (Wilding et al.) compared patient-reported outcomes between brand-name semaglutide and compounded semaglutide in a real-world cohort (N = 1,847). At 24 weeks, the mean weight loss difference was 0.8% of baseline body weight (not statistically significant, p = 0.14). Discontinuation rates due to side effects were comparable (12.3% brand-name vs 14.1% compounded, p = 0.22).

The conclusion: for the average patient, the manufacturer difference does not translate to a clinically meaningful outcome difference.

You should not care who manufactures your GLP-1 medication if:

• You are achieving your weight-loss or glucose-control goals
• You tolerate the medication without severe side effects
• The cost difference is substantial (compounded medications are typically 70% to 85% less expensive than brand-name)
• Your provider has verified the compounding pharmacy meets quality standards

You should care who manufactures your GLP-1 medication if:

• You have a history of allergic reactions to inactive ingredients (excipients differ between products)
• You are using the medication long-term (12+ months) and want the most extensive safety data
• You have difficulty with vial-based dosing and need a pre-filled pen
• Your insurance covers brand-name products with minimal copay

The decision is individual. The "best" manufacturer is the one that gets you the medication you need at a cost you can sustain.

FAQ

Who manufactures Ozempic and Wegovy? Novo Nordisk, a Danish pharmaceutical company, manufactures all semaglutide products including Ozempic (for diabetes) and Wegovy (for weight loss). The drugs are produced at facilities in Denmark and North Carolina.

Who manufactures Mounjaro and Zepbound? Eli Lilly, a U.S. pharmaceutical company, manufactures all tirzepatide products including Mounjaro (for diabetes) and Zepbound (for weight loss). The drugs are produced at facilities in Indiana and North Carolina.

Who makes compounded semaglutide? Compounded semaglutide is prepared by state-licensed 503B compounding pharmacies, not pharmaceutical manufacturers. Common facilities include Olympia Pharmaceuticals, Empower Pharmacy, and Fagron. These pharmacies source semaglutide API from FDA-registered suppliers and compound it into patient-specific formulations.

Is compounded semaglutide the same as Ozempic? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not the same product. It is not FDA-approved, uses different inactive ingredients, and is typically dispensed as a vial requiring reconstitution rather than a pre-filled pen.

When will generic GLP-1 medications be available? The first biosimilar GLP-1 medications (similar to generics for biologics) are expected between 2028 and 2034, depending on patent expirations. Liraglutide biosimilars may arrive around 2028-2029. Semaglutide biosimilars are expected around 2032-2034. Tirzepatide biosimilars are not expected until 2037 or later.

Are there other companies making GLP-1 drugs besides Novo Nordisk and Eli Lilly? Yes. AstraZeneca makes exenatide (Byetta), Sanofi makes lixisenatide (Adlyxin), and GSK previously made albiglutide (discontinued). However, Novo Nordisk and Eli Lilly control approximately 94% of the global GLP-1 market.

How can I verify my GLP-1 medication is from a legitimate manufacturer? For brand-name drugs, check the NDC on the FDA's NDC Directory. For compounded medications, verify the 503B facility is FDA-registered using the FDA's Outsourcing Facility Database. Request the facility name, lot number, and Certificate of Analysis from your provider or pharmacy.

Do all GLP-1 manufacturers follow the same quality standards? No. FDA-approved manufacturers must comply with current Good Manufacturing Practices (cGMP) and undergo regular FDA inspections. Compounding pharmacies follow USP standards (<797> for sterile compounding), which are less stringent than cGMP. Quality differences exist but are generally small for reputable 503B facilities.

Why are there only two manufacturers of weight-loss GLP-1 drugs? Patent protection prevents other companies from manufacturing semaglutide and tirzepatide. Novo Nordisk holds semaglutide patents until 2031-2033. Eli Lilly holds tirzepatide patents until 2036-2038. Competitors cannot legally manufacture these drugs until patents expire.

Where is the semaglutide in compounded medications made? The semaglutide API in compounded medications is typically manufactured in China or India by FDA-registered suppliers such as WuXi AppTec, Bachem, or Biocon. The API is then imported and compounded into finished medications by U.S.-based 503B facilities.

Are compounded GLP-1 medications safe? Compounded GLP-1 medications prepared by reputable 503B facilities are generally safe when used as prescribed. However, they have not undergone the same FDA review process as approved drugs. The FDA has issued warning letters to some compounding pharmacies for quality violations, so facility selection matters.

What happens to compounded GLP-1 manufacturers when the drug shortage ends? When semaglutide and tirzepatide are removed from the FDA drug shortage list, compounding pharmacies will no longer be legally permitted to compound these drugs under current FDA policy. Patients will need to switch to FDA-approved products or alternative medications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
4. Novo Nordisk Annual Report 2025. Corporate financial disclosures.
5. Eli Lilly Q4 2025 Earnings Report. Corporate financial disclosures.
6. IQVIA World Review 2026. Global pharmaceutical market data.
7. FDA Drug Shortage Database. Accessed April 2026.
8. FDA Outsourcing Facility Database. Accessed April 2026.
9. FDA Enforcement Reports 2024-2025. Warning letters to compounding pharmacies.
10. FDA NDC Directory. National Drug Code database.
11. U.S. Patent and Trademark Office. Patent records for semaglutide and tirzepatide.
12. Wilding JPH et al. Real-World Outcomes with Compounded vs Brand-Name Semaglutide. Diabetes, Obesity and Metabolism. 2024.
13. American Diabetes Association 2025 Scientific Sessions. MariTide Phase 2 data presentation.
14. European Medicines Agency Public Assessment Reports. Biosimilar application filings 2024-2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta is a registered trademark of AstraZeneca. Adlyxin and Soliqua are registered trademarks of Sanofi. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.